Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma - Summary - MDSpire

Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma

  • By

  • Karan L. Chohan

  • Rina L. Welkie

  • James Godfrey

  • Steven Bair

  • Lorenzo Falchi

  • Manali Kamdar

  • Ajay Major

  • Wendy Dixon

  • Jennifer Crombie

  • Reid Merryman

  • Sonia Godbole

  • Gilles Salles

  • Omnia Farahat

  • Amy Ayers

  • Ayushi Chauhan

  • Alex Herrera

  • Geoffrey Shouse

  • Sairah Ahmed

  • Yazeed Sawalha

  • May 22, 2026

  • 0 min

Share

Objective:

To report multicenter outcomes of CD3xCD20 bispecific antibodies (BsAbs) in patients with active or prior history of CNS involvement by aggressive B-cell non-Hodgkin lymphoma (B-NHL).

Key Findings:
  • In patients with active CNS involvement (n=18), the overall response rate (ORR) was 56%, with a complete response (CR) rate of 33%.
  • In patients with prior CNS involvement (n=10), the ORR was 60%, with a CR rate of 50%.
  • The median time to best CNS response was 58 days.
  • 6-month progression-free survival (PFS) was 43% for active CNS involvement and 46% for prior CNS involvement.
  • 6-month overall survival (OS) was 77% for active CNS involvement and 89% for prior CNS involvement.
Interpretation:

Limitations:
  • The study is retrospective and includes a small sample size.
  • Patients with active CNS involvement were excluded from pivotal trials, limiting generalizability.
  • The safety profile in patients with prior CNS involvement but no active disease is not fully characterized.
Conclusion:

Original Source(s)

Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma

  • by Karan L. Chohan, Rina L. Welkie, James Godfrey, Steven Bair, Lorenzo Falchi, Manali Kamdar, Ajay Major, Wendy Dixon, Jennifer Crombie, Reid Merryman, Sonia Godbole, Gilles Salles, Omnia Farahat, Amy Ayers, Ayushi Chauhan, Alex Herrera, Geoffrey Shouse, Sairah Ahmed, Yazeed Sawalha

  • May 22, 2026

Related Content

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report